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Characterization of Streptococcus pyogenes Isolates from 
Lebanon: Pathogenesis, Epidemiology and Resistance 
 
Nathalie Mahmoud Karaky 
Abstract 
Streptococcus pyogenes (Group A Streptococcus [GAS]) is one of the clinically 
most important human pathogens responsible for numerous diseases with diverse 
clinical manifestations. GAS infections range from mild superficial skin infections to 
life-threatening systemic diseases associated with high morbidity and mortality rates. As 
the epidemiology of GAS infections changes, a rapid and trustworthy characterization of 
the isolates is required for epidemiological analysis and infection control. This study 
aimed at the molecular characterization of GAS isolated from Lebanon. Isolates were 
characterized by emm typing, superantigen and antibiotic profiles. Fourty-one distinct 
emm types were detected among the 150 isolates, the most prevalent of which were emm 
types: 89 (16%), 12 (10%), 2 (9%) and 1 (8%), previously associated with invasive 
infections. Five isolates were non-typeable. Antibiotic susceptibility testing against 
seven different classes revealed that all were susceptible to vancomycin, penicillin G and 
ampicillin, 9% were resistant to clindamycin, 23% were resistant to erythromycin and 
only 4% were resistant to erythromycin and clindamycin, showing the macrolide–
lincosamide–streptogramin B phenotype. An unexpected high emergence of tetracycline 
resistant strains (37%) was noted and hence our results confirm that resistance of S. 
pyogenes is a significant problem in Lebanon. Testing for superantigen showed that 
SpeB (87%) followed by ssa (36%) and SpeG (30%) were the predominant 
superantigens recovered, but no clear conclusion was excluded from this study 
concerning the role of superantigens in disease manifestation. This study provides a 
database of emm sequences, resistance patterns and superantigen profiles of S. pyogenes, 
which will assist in long-term epidemiological and evolutionary studies of this 
x 
 
significant pathogen in Lebanon. Further surveillance studies are required to understand 
the local epidemiology of GAS in Lebanon. 
 
Keywords: Streptococcus pyogenes, GAS, emm typing, Superantigens, Antibiotics. 
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CHAPTER ONE 
INTRODUCTION 
 
Group A Streptococcus (GAS), Streptococcus pyogenes, is a highly prevalent 
human pathogen with a global distribution (Meisal et al. 2010). This bacterium was first 
identified in 1874 but did not gain much attention until late 1980s after the sudden 
increase in severe GAS infections. GAS is part of the nasopharyngeal flora in 5-15% of 
humans and is held responsible for a wide variety of non-invasive infections including 
pharyngo-tonsillitis and skin infections to more invasive arthritis, septicemia, 
necrotizing fasciitis, cellulitis, meningitis, pneumonia and streptococcal toxic shock 
syndrome (STSS) (Harari et al. 2008). GAS is spread by respiratory droplets and 
fomites, hence, the incidence of GAS respiratory infections peaks in childhood (Tartof et 
al. 2010).  
Several virulence factors contribute to the complex pathogenicity of S. pyogenes 
including the cell surface anti-phagocytic M protein, streptolysins (O and S), 
hyaluronidase, C5a peptidase, streptokinase as well as other extracellular products (Cole 
et al. 2011). The potent immunostimulators, streptococcal pyrogenic exotoxins (Spe 
proteins), have been closely associated with severe disease manifestations such as acute 
rheumatic fever, scarlet fever and STSS (Meisal et al. 2010; Proft et al. 2003). 
To date, penicillin remains the treatment of choice for GAS infections (Rijal et 
al. 2009) with macrolides and lincosamides being first-line alternatives for patients 
having allergy against ß-lactams (Ardanuy et al. 2010). But still, the increase in the 
incidence of resistance against those antibiotics as well as other current used antibiotics 
highlights the need to assess the evolution of resistance of this pathogen to antibiotics. 
Due to the increased reports of GAS infections mainly in developing countries, 
epidemiological studies based on molecular approaches, are becoming indispensable for 
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the identification and control of streptococcal infections. By tracing selected virulence 
factors such as M types, superantigen genes and antibiotics profiles, insight of the 
pathogenic mechanism of this pathogen would be enhanced (Harari et al. 2008). 
In this study, we report the molecular characterization of 150 S. pyogenes 
isolates collected at AUB-MC from Lebanon between August 2010 and November 
2011. emm typing and detection of superantigen genes were used as molecular 
techniques to differentiate GAS isolates. The objectives of this study were to (i) 
determine patterns of emm types and superantigen genes (ii) gain clearer understanding 
of the changes in the epidemiology of S. pyogenes isolates associated with infections 
among the Lebanese population, (iii) determine antibiotic susceptibility profiles of GAS 
isolates using both disc-diffusion and E-tests methodologies, (iv) ascertain comparative 
analysis with other correlated studies in the region, especially with those from Lebanon. 
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CHAPTER TWO 
LITERATURE REVIEW 
 
2.1 Overview of Streptococcus pyogenes 
 Streptococcus pyogenes is an exclusive human pathogen and the causative agent 
for several diseases mainly respiratory tract, bloodstream and skin infections (Harari et 
al. 2008). S. pyogenes is commonly known as GAS (Group A Streptococcus) since it 
expresses the Lancefield group A carbohydrate (Sriskandan et al. 2007). Streptococcus 
comes from the Greek word strepto (twisted) and coccus (spherical). To date, more than 
hundred recognized species of Streptococcus were identified (Nobbs et al. 2009).  
GAS is a gram positive, non motile, non spore-forming, catalase negative 
bacterium. Microscopically, GAS appears as round to ovoid cocci occurring in pairs or 
chains ranging in size between 0.1-0.6 µm in diameter. The bacterium is a facultative 
anaerobe but some others are facultative aerobes. For its optimal growth, enriched media 
such as blood agar and a temperature of 37˚C with 21% O2 and 5% CO2 are required. 
The production of streptolysin S (SLS) and Streptolysin O (SLO) toxins that lyse red 
blood cells results in a clear zone surrounding the bacterial mucoid colonies hence the 
name Group A beta hemolytic Streptococci (GABHS). GABHS is distinguished by its 
sensitivity to bacitracin which differentiates it presumptively from other ß-hemolytic 
streptococci (Todar 2000). 
GABHS are ubiquitous in the environment and cause a wide array of human 
infections associated with high morbidity and mortality, the most frequent of which is 
pharyngitis, tonsillitis and more invasive infections such as bacteremia, pneumonia, 
scarlet fever and streptococcal toxic shock syndrome (Lin et al. 2011). GAS 
pathogenesis is attributable to a variety of virulence factors and these include M protein 
and lipoteichoic acid that promotes attachment upon bacterial entry, hyaluronic acid 
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capsule that prevents phagocytosis, as well as other secreted extracellular products that 
play a role in aggravation of harmful inflammatory responses such as pyrogenic toxins, 
streptolysins, and streptokinase (Petterson 1996; Sriskandan et al. 2007). Streptococcus 
superantigens, extracellular protein toxins, are the most powerful T cell mitogens ever 
discovered that can obstruct the development of a protective host immune response 
during the course of infection (Proft and Fraser 2003; Bohach et al. 1990). 
For treatment of GAS infections, physicians have relied on the fact that it is 
remaining globally susceptible to penicillin, but increased resistance to different 
antibiotic classes, especially macrolides, lincosamides and tetracycines, have been 
reported (Martin and Green 2006; Billal et al. 2009; Gracia et al. 2009; Malhotra-Kumar 
et al. 2009). The complexity of some GAS infections may necessitate the need for more 
aggressive treatments and surgical interventions (Cole et al. 2011). 
 
2.2 Occurrence 
Although GAS is considered a normal flora of the respiratory tract, skin, vagina 
and anus in 15-20% of normal individuals, it is estimated that this bacterium is 
responsible for 700 million cases of mild, non-invasive infections every year (Arguelles 
et al. 2004); among which 650,000 cases turn into severe invasive infections associated 
with a 25% mortality (Carapetis et al. 2005). In 2011, a significant upsurge in mortality 
rates due to GAS diseases was noted to attain 500,000 cases worldwide each year (Lin et 
al. 2011). The first description of S. pyogenes by Billroth dates back to 1874 from 
wound infected patients. Nine years later, the same chain-forming organism was 
observed by Fehleisen from perierysipelas lesion and it was named afterward by 
Rosebach in 1884 (Graziella et al. 2001). The conventional diseases caused by GAS 
range from suppurative mild pharyngitis and skin infections to more invasive infections 
affecting the blood, deep tissues and multiple organs. The rate of such severe 
complications decreased dramatically from mid 1970’s till 1990’s and the interest in this 
potent bacterium in particular began to fade. However, GAS regained its glory in the late 
1980’s after the report of an upsurge of invasive clinical infections (namely rheumatic 
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fever, bacteremia and STSS) in several countries (Efstratiou et al. 2000; Ma et al. 2009). 
This was attributed to several virulence factors including M protein, streptococcal 
superantigens, as well as a significant increase in antibiotics resistance. Host factors, 
including age, underlying disease (varicella, diabetes, any acute or chronic skin lesion), 
sedentary lifestyle (drug injections) and environmental factors (household size and 
overcrowding) has also played a role in the underlying pathogenicity (Factor 2003; 
Stevens 1992; Arguelles et al. 2004; Durmaz et al. 2003). 
 
2.3 Pathogenesis of Streptococcus pyogenes 
Being part of the normal flora, S. pyogenes compete in number with the 
microbial nasopharyngeal ecosystem and they are limited by the non specific host 
defense mechanisms. However, disease occurs upon alteration of these mechanisms and 
the acquisition of new strains disturbing the normal flora. GAS infections can be 
subdivided into four categories: superficial (pharyngitis, skin and soft tissue infections, 
impetigo, erysipelas, vaginitis, and post-partum infections), deep invasive infections 
(bacteremia, necrotizing fasciitis, deep soft tissue infections, cellulitis, myositis, 
puerperal sepsis, pericarditis meningitis, cellulitis, pneumonia and septic arithritis), 
toxin-mediated diseases (scarletina and toxic shock syndrome) and lastly non-
suppurative streptococcal sequelae (acute rheumatic fever, post-streptococcal 
glomerulonephritis, reactive arithritis and reactive heart disease) (Cole et al. 2011). 
Various virulence factors are required to facilitate the pathogen-host interaction and 
subversion’s of the host’s immune system (Cole et al. 2011). These factors comprise 
genes for erythrogenic toxins, streptococcal superantigens, cytolysins, C5a peptidase, 
hyaluridonic  acid capsule (HLA), M and M-like proteins and Streptococcal Inhibitor of 
Complement (SIC) protein (Efstartiou et al. 2000). Following colonization of host 
epithelial tissues, surface-expressed M protein binds fibrinogen, complement inhibitory 
factor H, C4b-binding protein and immunoglobulin Fc regions, mediating adhesion to 
host cells and resistance to opsonophagocytosis by plymorphonuclear cells (Horstman et 
al. 1992; Staali et al. 2006). GAS evasion of host immune responses is also made 
possible due to the molecular mimicry existing between the host connective tissue and 
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GAS hyaluronic acid capsule rendering it non-antigenic (Cunnigham et al. 2000). 
Secreted extracellular products such as SLO, C5a peptidase, IL-8 protease, SIC, 
streptokinase and others play as well an important role in GAS pathogenesis. In 
particular, these enhance GAS escape from the responsive pathways by forming large 
pores in host cell membranes (Bhakdi et al. 1985), inhibiting innate immune system 
molecules and inducing apoptosis of epithelial cells, neutrophils and macrophages 
(Timmer et al. 2009). The pyrogenic extracellular protein toxins known as 
“superantigens” are also considered essential virulence factors of GAS. These proteins 
act by suppressing immunoglobulin production rendering the host susceptible to 
endotoxic shock. Having also a mitogenic activity for specific T cell subsets, 
superantigens are held responsible for shock and widespread organ damage by triggering 
an extensive immune response and release of pro-inflammatory cytokines, such as 
tumour necrosis factor α, IL-6, IL-2 and γ-interferon (Cutis 1996; Commons et al. 2008). 
 
2.4 Antibiotic susceptibility testing 
In spite of the extensive use of ß-lactams against GAS infections for more than 
half a century, resistance was not affirmed until recently by Ogawa et al. (2011). The 
characterization of presumed penicillin resistant isolates as well as their resistance 
mechanism is still under investigation. Sawai et al. (2007), however, had reported a 
decreased efficacy for penicillin against invasive infections. Despite that, penicillin and 
its derivatives are still the treatment of choice for S. pyogenes diseases (Gracia et al. 
2009).  
Macrolides and lincosamides are considered therapeutic alternatives to treat GAS 
diseases in ß-lactam allergic patients (Gracia et al. 2009). Yet, an increasing resistance 
to macrolides is described all over the world, chiefly in European and Asian countries 
(Ardanuy et al. 2010; Ciftci et al. 2008; Gracia et al. 2009). Erythromycin resistance was 
detected in 1956 for the first time in Staphylococcus species and three years later in 
Streptococci (Leclercq 2002). Two main mechanisms are responsible for the associated 
resistance: (i) resistance encoded by chromosomal mefA and mefE genes, an active 
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efflux pump that affects the 14- and 15-member-ring macrolides (the M resistance 
phenotype) (Clancy et al. 1996; Sutcliffe et al. 1996). mef genes are constitutively 
expressed and can be transferred by conjugation (Kataja et al. 2000); (ii) resistance 
encoded by the erm genes (ermA and ermB) and mediated by methylases, considered 
less specific and a target site modification (Seppala et al. 1998; Weisblum 1995). In 
particular, the A2058 methylation of the peptidyl transferase is accountable not only for 
macrolide resistance but also for resistance against lincosamides and streptogramin B as 
well, resulting in what is known as MLSB phenotype (Weisblum 1995). The erm genes, 
inducibly or constitutively expressed, are carried on both chromosomes and plasmids 
(Ceglowski and Alonso 1994) and are associated with conjugative transposons. 
Interestingly, several studies have reported a sturdy decrease of erythromycin resistance 
in GAS isolates from different countries around the world (Japan, Korea, Italy, and 
Spain) (Billal et al. 2009; Fujita et al. 1994; Hseuh et al. 2006; Montagnami et al. 2006; 
Oliver et al. 2007; Uh et al. 2007). This phenomenon was attributed to either a reduction 
in use of erythromycin or a shift in the most prevalent emm types (Billal et al. 2009).  
 
In spite of the fact that tetracyclines are no longer used for the treatment of GAS 
infections, GAS susceptibility to tetracyclines is remarkably variable among countries. 
Tetracycline resistance is mediated by tet(M) and tet(O) genes that encode ribosomal 
protection proteins and tet(K) and tet(L), both of which encode efflux proteins 
(Giovanetti et al. 2003). A close association between erythromycin and tetracycline 
resistance in S. pyogenes became apparent as tet(O) was found to be linked to ermA and 
mefA genes respectively in tetracycline-resistant isolates of either M or iMLS-B 
phenotypes (Brenciani et al. 2007). 
 
On the other hand, resistance to fluoroqinolones is not frequently encountered at 
present, but it is still a main cause of concern. Fluoroquinolones are prescribed for 
patients with ß-lactam allergy as an alternative of macrolides in the light of increasing 
resistance worldwide. Noting that quinolones are not recommended to treat respiratory 
infections caused by S. pyogenes but still levofloxacin and moxifloxacin has illustrated 
good activity against penicillin- or macrolide-resistant strains (Malhotra-Kumar et al. 
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2009). Resistance against fluoroquinolones can be summarized by a point mutation in 
parC and parE genes, encoding topoisomerase IV and DNA gyrase (gyrA and gyrB) 
mainly in the quinolone resistance determining region (QRDRs) (Malhorta-Kumar et al. 
2005). Another frequent mechanism of resistance is the repersine-sensitive pump which 
is very well demonstrated for Streptococcus pneumonia but still under investigation for 
S. pyogenes (Piddock 1999). 
2.5 Molecular typing of Streptococcus pyogenes 
In the early 1980s, there was complacency about the necessity for GAS 
serotyping and several laboratories decreased their in-house production of M typing 
sera. However, the resurgence of invasive disease caused by GAS resulting in increased 
reports of septicemia, necrotizng fasciitis (NF) and STSS in healthy children and adults 
in the United States and Europe in the mid to late 1980s necessitated the consideration of 
molecular approaches (Meisal et al. 2010; Efstratiou 2000). The first molecular methods 
used and documented were not associated with the classical M typing system, such as 
the Vir typing, developed first in Australia, using primers targeting the entire virulence-
regulating gene mga (Gardiner et al. 1998). Other methods targeting specific areas of the 
emm gene encoding the M protein were also developed such as oligonucleotide typing or 
dot blotting (Kaufhold et al. 1994) and PCR emm gene ELISA (Saunders et al. 1997). 
However, these methods required too many probes (at least 35 different emm probes) to 
cover the full range of S. pyogenes types. Therefore, new subtyping methods were 
generated to undertake population genetic studies such as ribotyping, multilocus enzyme 
electrophoresis (MLEE), pulsed field gel electrophoresis (PFGE), fluorescent amplified 
length polymorphisms (FAFLP) and multi-locus sequence typing (MLST) (Efstratiou 
2000). 
2.5.1 emm typing 
emm sequence typing, a band-based molecular technique that targets the M 
protein, was developed by the Centers for Disease Control and Prevention (CDC) and  is 
regarded as the most important indicator for invasiveness of GAS infections (Lintges et 
 9 
 
al. 2010). M proteins are dimeric, α-helical, coiled protein molecules which bind host 
surfaces at the C-terminal end while their N-terminal end contains a hypervariable 
region responsible for type specificity (Efstratiou et al. 2000). emm typing is based on 
the identification of more than 160 bases following amplification of the 5’ terminal end 
of the hypervariable chromosomal region of the M protein gene. A unique emm type is 
defined as having less than 95% sequence identity to any other known emm type over 
the 160 bp. In addition to sequence identity, insertion/ deletions (InDels) of four or 
fewer codons and/or frameshift mutations relative to the emm typing strain are allowed 
for classification as an established emm type. New emm types are allocated as “emmst” 
standing for emm sequence type until validation is complete (Enright et al. 2001). To 
date, more than 200 emm types are recognized throughout the world (Cole et al. 2011). 
2.5.2 Superantigens detection 
Superantigens have gained a good deal of attention since the sighting of their 
mechanisms back in 1989. Bacterial superantigens are 25 KDa soluble non-glycosylated 
molecules attached to the bacterial cell surface through their carboxyl terminal. To date, 
11 superantigens have been identified for S. pyogenes: the pyrogenic exotoxins (SpeA, 
SpeC, SpeG, SpeH, SpeI, SpeJ, Spek, SpeL, and SpeM), the streptococcal superantigen 
(ssa) and the streptococcal mitogenic exotoxin (smeZ). They all possess a signal N-
terminal sequence which is chopped at the bacterial cell surface promoting extracellular 
secretion. Upon crystallographic examination, SpeA, SpeC, SpeH, SpeJ and smeZ 
revealed a distinctive conserved structure encompassing an N-terminal barrel shape 
domain and a C-terminal grasp domain with an extending central helix linking both ends 
(Sriskandan et al. 2011; Proft and Frazer 2003). Based on these conserved amino acid 
sequences, scientists are able to discover new toxins for S. pyogenes and Staphylococcus 
aureus (Profet et al. 1999). Superantigens act by binding and cross linking the host 
major histocompatibility complex (MHC) class II molecules and the variable region of 
the T cell receptor (TCR) beta chain in a close manner, triggering thus a substantial 
release of inflammatory cytokines, leading to an excessive immune response and hence 
damage to the host (Mitchell et al. 2000). Most genes encoding GAS superantigens are 
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associated with bacteriophages excluding SpeG, SpeJ and smeZ which are assumed to be 
chromosomally related (Commons et al. 2008; Feretti et al. 2001). Being located on a 
mobile genetic element, these three genes are believed to have undergone horizontal 
gene transfer from across species (Igwe et al. 2003; Hashikawa et al. 2004). In 
particular, streptococcal superantigens are strongly linked to staphylococcal 
superantigens and it is more likely that horizontal gene transfer from S. aureus was the 
reason of the existence of this GAS superantigen subgroup rather than evolving from 
existing streptococcal superantigen genes (Commons et al. 2008; Profet and Fraser 
2003). Epidemiologically, STSS as well as severe invasive streptococcal diseases have 
been robustly associated with the production of streptococcal pyrogenic exotoxins 
specifically SpeA (Stevens et al. 1989). Profile distribution of superantigen genes has 
been added as additional epidemiological tool in order to reveal the genomic 
heterogeneity and probable associations between these toxins and disease type (Green et 
al. 2005; Ma et al. 2011). 
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CHAPTER THREE 
MATERIALS AND METHODS 
 
3.1 Clinical isolates  
A total of 150 GAS isolates obtained from clinical specimens in the period 
between August 2010 and November 2011 were kindly provided by Dr. George Araj 
from the American University of Beirut Medical Center (AUB-MC) to be used in this 
study. The samples were recovered from throat (95.3%), pus (4%) and wound (0.66%) 
infections. Samples were distributed among 67 females (45%) and 83 males (55%) of all 
age categories including 106 (71%) cases being aged less than 18 years (57.3% of which 
were less than 10 years) and 44 (29%) cases above 18 years. The identity of the isolates 
were confirmed by ß-hemolysis on blood agar plates (BAP), colony morphology (thin 
smooth colonies), gram’s staining, negative catalase reaction and the inhibition 
screening test with a bacitracin disk (0.04u). The samples were streaked on BAP, 
designated as SN01-SN150 and stored in cryobanks at -80 °C.  
  
3.2 DNA extraction 
Isolates were grown overnight on BAP at 37°C with 5% CO2. DNA extraction 
was done using Nucleospin
®
 Tissue (Macherey-Nagel, Germany) according to the 
manufacturer’s instructions. The lysates were then stored at -20 °C until needed. 
3.3 Typing of the emm gene 
3.3.1 Pre-sequencing PCR 
Typing of the Streptococcus protein M (emm) locus was carried by first 
amplifying the emm gene. The amplification employed 20 µmol of the emm-for (5'- TAT 
T(C/G)G CTT AGA AAA TTA A -3') and 20 µmol of emm-rev (5'- GCA AGT TCT TCA 
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GCT TGT TT -3') primers in a 20μl mixture containing 2 μl DNA, 2 μl dNTPs, 2 μl of 
10X concentrated PCR Buffer II (Applied Biosystems), MgCl2 25mM, and 5U of 
AmpliTaq DNA polymerase (Applied Biosystems). Thermal cycling reactions consisted 
of an initial denaturation (12 min at 95 °C) followed by 30 cycles of denaturation (30 s 
at 95 °C), annealing (40 s at 46.5 °C), and extension (2 min at 72 °C), with a single final 
extension (10 min at 72 °C). The resulting DNA fragments were visualized by 7 µl of 
ethidium bromide staining on 1.5% agarose gel using 1X TAE buffer at 100V. 
3.3.2 EXOSAP-IT 
To purify the pre-sequencing PCR products, 4 µl of EXOSAP-IT (usb
®
) enzyme 
was added to 10 µl of the PCR products. The reactions consisted of 37 °C for 30 min, 80 
°C for 15 min and stored at 20 °C. 
3.3.3 Sequencing PCR 
The amplicons previously emm-typed were sequenced using the ABI Prism 
BigDye Terminator v3.0 Ready Reaction Cycle Sequencing Kit (Applied Biosystems). 
The sequencing reaction was conducted using 4 μl of 5X diluted Bigdye® premix, 3 µl 
of 1.2 µM sequencing forward primer, and 3 μl of the cleaned PCR product in a total 
volume of 10 μl. PCR cycling consisted of initial denaturation step at 96 ˚C for 1min 
followed by 26 cycles of denaturation (96 ˚C for 10 s), annealing (50 ˚C for 5 s) and 
extension (60 ˚C for 4 min). 
3.3.4 DNA Precipitation and Loading 
The sequencing products were purified using DyeEx
®
 2.0 Spin Kit (Qiagen, 
Hilden, Germany). The samples were dried in a vacuum centrifuge, and then 20μl of 
HiDi formamide were added (Applied Biosystems) as loading media for sequencing 
electrophoresis on an ABI 3500 Avant Genetic Analyzer (Applied Biosystems). The 
types subtypes of the sequences were assigned for the isolates by the curators of the CDC 
database (http://www.cdc.gov/ncidod/biotech/strep/M-ProteinGene_typing.htm) by BLAST 
comparison to emm sequences in the type-specific database. New subtypes were assigned by 
the curator of the database. 
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3.4 Antibiotic susceptibility testing 
All 150 S. pyogenes isolates were tested with respect to 14 antibiotics belonging to 7 
classes (ß-lactams, macrolides, lincosamins, fluoroquinlones, glycopeptides, phenicols 
and cyclines) using standard disk diffusion method following CLSI (2011) and 
EUCAST (2012) recommendations and criteria. The Minimum Inhibitory 
Concentrations (MICs) were determined as well for 11 antibiotics By E-test (AB 
Biodisk and oxoid). For each isolate, a Mueller-Hinton plate supplemented with 5% 
blood was inoculated with a bacterial suspension of 0.5McFarland turbidity (or 
10
5
CFU/ml). Plates were placed in a CO2 incubator for 18-24 h at 35-37 ˚C. S. pyogenes 
ATCC 12344 and 700294 were used as controls. Phenotypic characterization of 
macrolide resistance was evaluated using a disk diffusion test with erythromycin (15 µg) 
and clindamycin (2 µg) placed 20 mm apart on a blood agar plate. Following incubation, 
isolates that showed blunting of the inhibition zone around the clindamycin disk 
adjacent to erythromycin disk were considered to have an inducible MLSB (iMLSB) 
phenotype. Clinadamycin susceptible isolated without blunting were considered to have 
the M phenotype and these that were resistant to both discs are classified as constitutive 
MLSB (cMLSB). Table 1 summarizes the concentration (µg), along with the zone of 
inhibition (ZOI) and the MICs for each antibiotic as recommended.  
Table 1. Zone of  inhibition (mm) and MICs for the tested antibiotics according to CLSI, 2010  
Antibiotic (µg) ZOI (mm) MIC 
S I R S I R 
Ampicillin (10) ≥ 24 … … ≤ 0.25 … … 
Azithromycin (15) ≥ 18 14-17 ≤ 13 ≤ 0.5 1 ≥ 2 
Chloramphenicol (30) ≥ 21 18-20 ≤ 17 ≤ 4 8 ≥  16 
Ciprofloxacin (5) ≥21 16-20 ≤15 … … … 
Clarithromycin (15) ≥ 21 17-20 ≤ 16 ≤ 0.25 0.5 ≥ 1 
Clindamycin (2) ≥ 19 16-18 ≤ 15 ≤ 0.25 0.5 ≥ 1 
Dithromycin (15) ≥ 18 14-17 ≤ 13 ≤ 0.5 1 ≥ 2 
Erythromycin (15) ≥ 21 16-20 ≤ 15 ≤ 0.25 0.5 ≥ 1 
Levofloxacin (5) ≥ 17 14-16 ≤ 13 ≤ 2 4 ≥ 8 
Oflaxacin (5) ≥ 16 13-15 ≤ 12 ≤ 2 4 ≥ 8 
Penicillin (10) ≥ 24 … … ≤ 0.12 … … 
Teicoplanin (30) ≥15 … ≤15 ≤ 2 … ≥2 
Tetracyclines (30) ≥ 23 19-22 ≤ 18 ≤ 2 4 ≥ 8 
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3.5 Superantigen detection 
The protocol was adapted from Commons et al. (2008). The optimal cycling
 
conditions were the following: 95 °C for 15 min; 30 cycles
 
of 94 °C for 30 s, 57 °C for 
1.5 min, and 72 °C for 1.5 min; and a final extension at 72 °C for 10 min. For multiplex 
PCR, a Qiagen
®
 multiplex PCR kit was used. Reaction mixtures contained 1 µg of 
chromosomal
 
template; 25 µl master mix with 3 mM MgCl2, 5 µl primer mix (2 mM in 
TE buffer for each primer) and RNase-free water to a final volume of 50 µl. The PCR 
products (7 µl)
 
were resolved in a 1.8% (w/v) Metaphor (Lonza, Rockland, ME, USA) 
agarose
 
gel in 0.5% Tris-borate-EDTA buffer (Bio-Rad, Hercules, CA)
 
at 80 V/cm for 1 
h and were visualized with ethidium bromide. PCR primer sets (Table 2) were selected 
from published papers based on specificity, compatibility and ability to target fragments 
of streptococcal superantigens (Commons et al. 2008; Proft et al. 2001; Chatelier et al. 
2000). Staphylococcus aureus and Streptococcus pneumoniae genomic DNA were used 
as negative controls. As noted in Table 2, some of the primers yielded amplicons of very 
close sizes (SpeI and SpeL [approximately 700bp] and SpeK and SpeB [approximately 
800bp]); for this reason individual PCRs with corresponding primers were performed for 
strains with positive bands for these sizes 
 
Table 2. Primers used for the detection of the genes of the 12 streptococcal by multiplex PCR as described by 
Commons et al. (2008). 
Superantigen Forward primer Reverse primer 
Amplicon 
size (bp) 
SpeA CCAAGCCAACTTCACAGATC CCCTTCATGATTTGTTACCCC 309 
SpeC CTATGGTGGAATTACACC CAATTTCCTGGAAAGTTACG 140 
SpeG CTGGATCCGATGAAAATTTAAAAGATTTAA AAGAATTCGGGGGGAGAATAG 743 
SpeH TTGGATCCAATTCTTATAATACAACC CCACTTCCTGAGCGGTTACTTTCGG 399 
SpeI GGATCCATGAGTAGTGTGGGAGTTATTAA AAGCTTTTATTTATTAAATTTAACTAAG 690 
SpeJ CTATGGTGGAATTACACC CATGTTTATTGCCATTGATCGC 247 
SpeK GCGGATCCGATACGTACAATACAAATG GCGAATTCAATAGCATTCAACCA 798 
SpeL 
GCAGCCATATGGAAGAGACTATTCCTCTTAA
GGATATATACTCTC 
GGGGATCCTTAATTTTCTTTGTTTGTGAA
TAAATAGAC 
703 
SpeM GCAGCCATATGTTTTCAGATGCTGTGTTGG 
GGGGATCCTTAATTTTTAGAAAAATCTT
CGTTTAAGTA 
661 
Ssa TGAGGTAATTGGGGAGATGA CTAATTCTTGAACAGTGACTTG 621 
SmeZ TGGGATCCTTAGAAGTAGATAATA AAGAATTCTTAGGAGTCAATTTC 376 
speB II GGATCCCAACCAGTTGTTAAATCTCT AACGTTCTAAGGTTTGATGCCTACAA 774 
SpeJ GGATCCGATAGTGAAAATATTAAAGCG GAATTCGCTCCTATCTTATTTAGTCC 650 
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CHAPTER FOUR 
RESULTS 
4.1 emm type distribution 
Fourty-one different emm types were identified among the 150 S. pyogenes 
isolates with 145 showing interpretable emm sequences and 5 isolates being non-
typeable. The most prevalent emm types were emm type 89 (emm89; 16%), emm12 
(10%), emm2 (9%), and emm1 (8%). The detected emm types and their frequencies are 
shown in Table 3 and Figure 1. Comparison of emm type distribution in Lebanon in the 
study conducted in 2009 (Bahnan et al. 2010) and the distribution obtained in the current 
study is shown in Fig 3. The neighbor joining tree shown in Fig 2 illustrates the tangible 
evolutionary events among the observed emm types. 100% confidence levels were 
obtained for emm13 and emm76 and 99% between emm28 and emm22 and between 
emm118 and emm49. However, low confidence levels were observed for emm1.11 and 
emm1.0, and emm108 and StG166B. 
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Table 3. The emm types distribution within 150 collected S. pyogenes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1. The distribution (%) of the different emm types in the collected samples with emm89 being the 
predominant type (15.17%). 
 
emm type No. of isolates (%) emm type No. of isolates 
89 22 (15.17%) 1.57 1 (0.69%) 
12 13 (8.97%) 2.2 1 (0.69%) 
2 12 (8.28%) 4 1 (0.69%) 
1 11 (7.59%) 12.48 1 (0.69%) 
75 9 (6.21%) 13 1 (0.69%) 
108 8 (5.52%) 29.3 1 (0.69%) 
22 7 (4.83%) 49 1 (0.69%) 
6 6 (4.14%) 76 1 (0.69%) 
28 6 (4.14%) 85 1 (0.69%) 
29.2 5 (3.45%) 87 1 (0.69%) 
STG7882.1 5 (3.45%) 89.1 1 (0.69%) 
NT 5 (3.45%) 94 1 (0.69%) 
11 4 (2.76%) 118 1 (0.69%) 
9 3 (2.07%) ST0412.0 1 (0.69%) 
12.1 3 (2.07%) ST3211.0 1 (0.69%) 
STC5345.1 3 (2.07%) ST5240.0 1 (0.69%) 
12.7 2 (1.38%) STC1400 1 (0.69%) 
77 2 (1.38%) STC6779.0 1 (0.69%) 
1.11 1 (0.69%) STG166B.0 1 (0.69%) 
1.44 1 (0.69%) STG652 1 (0.69%) 
1.51 1 (0.69%)   
NT, Not typeable 
emm types in bold are types newly identified in Lebanon 
ST- STC- STG and STGM are emm sequence types from group A Streptococci not yet given the "emm " designation 
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Fig 2. Neighbor-Joining tree of the representative emm types.  
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Fig 3. Comparison of distribution of emm types between the study conducted by Bahnan et al. (2011) and this 
study 
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4.2 Distribution of superantigen genes in S. pyogenes 
 Isolates used to determine the distribution of SAg genes were selected to be of 41 
different emm types. Multiplex PCR assay (Fig 4) revealed the presence of 1 to 5 genes, 
the most frequent detected being SpeB, ssa and SpeG in 87%, 36% and 30% of the 
isolates, respectively. The phage associated SpeA gene was detected in 28% of the 
isolates, while only 2% were positive for SpeC, while only a single isolate harbored the 
SpeI gene. Table 4 shows the percentage distribution of Spe genes, ssa and smeZ among 
the 100 tested strains. In 52% of the strains, only two of the 11 SAg genes studied were 
detected, whereas in 38% of the strains three genes were found and only one isolate had 
all 5 genes. The 100 isolates displayed 41 distinct superantigen profiles. The 4 major 
profiles accounted for 24% of the strains whereas the top 10 profiles accounted for 51% 
of the total number of the strains. Profiles’ distribution among different emm types is 
shown in Table 5. 
 
 
Fig 4. Agarose gel electrophoresis showing representative PCR products after SAg detection. Lane 1, lane 9 
(L1,L3) and lane 2(L2) show 100bp and 50bp DNA marker respectively (Fermentas); Lanes 3-8 and 10-15 
show PCR products after SAg genes amplificationwith sizes between 309bp and 774 bp. 
 
 
 
 
 
 
 
 
 
L1       L2      1       2         3       4        5        6        L3       7        8       9        10     11      12 
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       Table 4. Percentage distribution of superantigen genes among 100 tested isolates. 
Superantigen genes Percentage (%) distribution 
SpeA 28 
SpeB 87 
SpeC 1 
SpeG 30 
SpeH 5 
SpeI 1 
SpeJ 11 
SpeK 20 
SpeL 22 
SpeM 3 
Ssa 36 
smeZ 9 
Spe: Superantigen pyrogenic exotoxin; sme Z: streptococcal mitogenic exotoxin; ssa: streptococcal superantigen. 
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emm type Positive genes No. of total isolates 
1 
SpeB – smeZ 
SpeA- SpeB- Spe L 
SpeB- ssa 
SpeA- SpeB 
SpeA-SpeB- SpeJ 
2 
2 
1 
3 
2 
1.11 SpeA-SpeB 1 
1.44 SpeA-SpeB- SpeJ 1 
1.51 SpeA-SpeB 2 
1.57 SpeA-SpeB-SpeI 1 
2 
 
SpeB-SpeJ-SpeK-ssa 
SpeG-SpeH-SpeK-ssa 
1 
1 
2.2 SpeB-SpeH-ssa 1 
4 SpeB-SpeG-SpeL- ssa 1 
6 
SpeB-SpeK 
SpeB-SpeL 
SpeB-SpeK- ssa 
SpeB-SpeK-SpeL-ssa 
2 
1 
2 
1 
9 SpeB- ssa 2 
11 SpeB- smeZ 1 
12 
SpeB-SpeL 
SpeB-SpeL-ssa 
SpeB-SpeG-ssa 
SpeA-SpeB-SpeM-ssa 
SpeB-SpeG 
SpeB-SpeJ 
1 
2 
3 
1 
3 
1 
13 SpeB-ssa 1 
22 
 
SpeA-SpeB-ssa 
SpeB-SpeG 
SpeA-SpeB-ssa-smeZ 
SpeB-SpeG-ssa 
2 
2 
1 
1 
28 
SpeB-SpeL-ssa 
SpeB-ssa 
2 
1 
29.2 
SpeB-SpeK 
SpeB-SpeG 
1 
2 
29.3 SpeG-SpeK-ssa 1 
49 SpeA-SpeH-SpeJ-SpeK-smeZ 1 
 
 
75 
SpeK-SpeL 
SpeA-SpeL 
SpeB-SpeK 
SpeB-SpeL-ssa 
SpeA-SpeM-ssa 
1 
1 
1 
1 
1 
76 SpeB-ssa 1 
77 
SpeB-smeZ 
SpeB-SpeJ 
1 
1 
85 SpeA-SpeH-ssa 1 
87 SpeB-SpeG 1 
 
 
 
89 
SpeB-SpeL 
SpeB-SpeG-ssa 
SpeB 
SpeA-SpeB-SpeG 
SpeB-SpeG-SpeJ 
SpeB-SpeG 
SpeB-SpeK 
2 
1 
2 
1 
2 
2 
2 
89.1 SpeB-SpeG 1 
94 SpeB-SpeG-SpeL 1 
108 
SpeB-SpeJ 
SpeB-SpeL 
SpeB-SpeJ-SpeL 
SpeM-ssa 
SpeB-ssa 
2 
1 
1 
1 
1 
118 SpeB-SpeH-SpeK- smeZ 1 
ST0412.0 SpeA-SpeK 1 
ST3211.0 SpeB-SpeK 1 
ST5240.0 SpeA-SpeB 1 
STC1400 SpeB-SpeG- smeZ 1 
STC5345.1 
SpeG-SpeK-ssa 
SpeB-SpeC-SpeK 
2 
1 
STC6779.0 SpeB-smeZ 1 
STG166B.0 SpeL-ssa 1 
STG652 SpeB-ssa 1 
STG7882.1 SpeA-SpeB-SpeG 4 
STGM220 SpeB-SpeJ-ssa 1 
Spe: Superantigen pyrogenic exotoxin; sme Z: streptococcal mitogenic exotoxin; ssa: streptococcal superantigen. 
 
Table 5. emm types versus superantigen profiles 
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4.3 Antibiotic susceptibility testing 
Out of the 150 isolates, 70 (46.6%) were sensitive to all tested antibiotics, while 
within the remaining 80 (53.3%) resistance was detected to one or more of the antibiotics 
used in this study. GAS strains indicated a relative high rate of resistance towards 
erythromycin (21.3%), followed by clindamycin (8.66%) and ciprofloxacin (5.3%) using 
disc diffusion method. Upon further testing using E-test, additional isolates were confirmed 
as resistant to tetracyclines (37%), erythromycin (23%), ciprofloxacin and clindamycin (9% 
each). On the basis of erythromycin-clinadmycin double-disk test, almost 1% of the 
erythromycin-resistant strains were assigned to the induced Macrolides-Lincosamide 
Streptogramin B phenotype (iMLS), 3% were assigned to the constitutive Macrolides-
Lincosamide Streptogramin B (cMLS) phenotype and only 2% displayed the M phenotype. 
All isolates were sensitive to penicillin, gentamycin, quinupristin/dalfoprustin, teicoplanin, 
ceftriaxone and vancomycin. Resistance of the isolates to the different antibiotics used in 
this study is shown in Fig.5. Thirty-three distinct resistant profiles for different antibiotics 
were generated using both the disc-diffusion and E-test methods (Tables 6 and 7). The most 
prevalent phenotypes accounted for erythromycin (16%), clindamycin (9.3%) and 
tetracycline-clarithromycin (5.3%), respectively. Association between antibiotic resistance 
and superantigen profiles is summarized in Table 8.  
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Fig5. Resistance rates of the 150 S. pyogenes strains using (A)Kirby-Bauer disc diffusion and (B) E-test 
methods. 
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           Table 6. Resistance profiles among S. pyogenes isolates using disc-diffusion method 
Resistant profile No. of isolates Percentage (%) 
ERY 20 13.3 
ERY-OFL 1 0.66 
ERY-CIP 1 0.66 
ERY-CHL-TET 1 0.66 
TET 8 5.33 
CIP 2 1.33 
CHL 6 4 
ERY CLI-CIP-TET 2 1.33 
ERY-CLI-CHL 3 2 
ERY-CLI-CHL-TET 2 1.33 
ERY-CLI-CHL-CIP-TET 2 1.33 
CLI 1 0.66 
CLI-TET 1 0.66 
CLI-CIP-TET 1 0.66 
CLI-CHL-TET 1 0.66 
CHL: chloramphenicol; CIP: ciprofloxacin; CLI: clindamycin; ERY: erythromycin; OFL: ofloxacin; TET: 
tetracyclines. 
 
                       Table 7. Resistance profiles among S. pyogenes isolates using E-test method  
Resistant profile No. of isolates Percentage (%) 
CLI 24 16 
CLI-LEV 1 0.66 
CLI-LEV-TET 1 0.66 
CIP 2 1.33 
CIP-TET 1 0.66 
ERY 14 9.33 
ERY-TET 5 3.33 
ERY-TET-CLI 1 0.66 
ERY-CIP-TET 2 1.33 
ERY-CIP-TET-CLI 1 0.66 
CLA 5 3.33 
CLA-TET 8 5.33 
CLA-TET-CLIN 2 1.33 
CLA-CIP-LEV-TET-CLI 1 0.66 
CLA-ERY 2 1.33 
CLA-ERY-CLIN 1 0.66 
CLA-ERY-TET 2 1.33 
CLA-ERY-TET-CLI 1 0.66 
CLA-ERY-CIP-TET 1 0.66 
CLA-ERY-CIP-TET-CLI 3 2 
CLA-ERY-CIP-LEV-TET-CLIN 1 0.66 
AZI-ERY-CIP-LEV-TET 1 0.66 
AZI: azithromycin; CHL: chloramphenicol; CIP: ciprofloxacin; CLA: clarythromycin; CLI: clindamycin; ERY: 
erythromycin; LEV: levofloxacin; OFL: ofloxacin; TET: tetracyclines. 
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Resistance Profile SAg Profile emm Type 
CHLO SpeB-SpeL-ssa 12 
CIP 
SpeB-SpeG-ssa 22 
SpeB-SpeL 12 
CIP-TET SpeB-SpeG 12.7 
CLA 
SpeB-SpeG 29.2 
SpeB-SpeJ 77 
SpeB-SpeG-smeZ STC1400 
CLA-CIP-CLIN-TET SpeB- ssa 9 
CLA-ERY 
SpeB-SpeK 75 
SpeA-SpeB ST5240.0 
CLA-TET 
SpeA-SpeB 1.11 
SpeA-SpeB- SpeL 1 
SpeA-SpeB-SpeG STG7882.1 
SpeA-SpeB-SpeJ 1 
SpeB- SpeL 108 
SpeB-SpeG 22 
SpeM-ssa 108 
CLI SpeB-smeZ 77 
CLI-TET-CLA-ERY SpeB- SpeL-ssa 28 
ERY 
SpeB-ssa 9 
SpeA- SpeB-ssa-smeZ 22 
SpeB-SpeK 29.2 
SpeK-SpeL 75 
SpeA-SpeH-ssa 85 
SpeB 89 
SpeA- SpeB-SpeG STG7882.1 
ERY-CIP-TET 
SpeB- SpeG 12 
SpeB-ssa 108 
ERY-CLA-CLIN-CHLO SpeA-SpeB-SpeG 89 
ERY-CLA-TET 
SpeL-ssa STG166B.0 
SpeB-SpeG 29.2 
ERY-TET 
SpeB-SpeG-ssa 89 
SpeB-ssa STG652 
SpeB-SpeJ- SpeK-ssa 2 
SpeB-SpeK 89 
TET 
SpeA- SpeB 1.51 
SpeA-SpeB-SpeL 1 
SpeA-SpeB-ssa 22 
SpeB 89 
SpeB SpeG 89.1 
SpeB- SpeG-SpeJ 89 
SpeB- SpeL-ssa 75 
SpeB-smeZ 1 
SpeB-SpeH-SpeK- smeZ 118 
SpeB-SpeH-ssa 2.2 
SpeB-SpeJ 108 
SpeB-SpeK 
6 
89 
SpeB-SpeK- SpeL-ssa 6 
SpeB-SpeK- ssa 6 
SpeB-ssa 76 
SpeG-SpeK-ssa 
29.3 
STC5345.1 
TET-CLA-CLIN SpeB- SpeL-ssa 12 
TET-CLIN SpeB-SpeL 89 
TET-LEV-CIP-ERY-CHLO SpeB- SpeJ -ssa STGM220 
Table8. Relationship of antibiotic resistance and superantigen profiles. emm  types are also included. 
 
AZI: azithromycin; CHL: chloramphenicol; CIP: ciprofloxacin; CLA: clarythromycin; CLI: clindamycin; ERY: erythromycin; 
LEV: levofloxacin; OFL: ofloxacin; TET: tetracyclines; Spe: Superantigen pyrogenic exotoxin; sme Z: streptococcal mitogenic 
exotoxin; ssa: streptococcal superantigen. 
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CHAPTER FIVE 
DISCUSSION 
 
Knowledge of epidemiology of GAS infections is indispensable for the 
appropriate decision-making in the treatment of infections as well as in limiting its 
spread. The current study presents a two year surveillance of GAS diseases in Lebanon, 
where 150 GAS isolates, collected between August 2010 and November 2011, were 
characterized using emm typing, toxin genes profiling and antibiotic resistance. Of the 
isolates, 95.3% were recovered from throat which is congruent with the prevalence of 
throat infections caused by GAS diseases (Nobbs et al. 2011; Cole et al. 2011; Martin et 
al. 2006). The distribution of GAS infections among males (55%) was higher than 
females (45%), a finding that was also reported by Lamagni et al. (2008) which opposes 
the common prevalence of GAS infections among females (Nobbs et al. 2011; Meisal et 
al. 2010). Sequential differences among male to female ratio among GAS patients, yet 
ambiguous, but may be affected by specific types of circulating strains. 
Occurrence of emm types among GAS isolates varies according to geographical 
locations, between and within individual countries (Ma et al. 2011). Bahnan et al. (2011) 
has reported the prevalence of emm1 (13%), emm2 (9%), emm28 (8%) and emm89 (8%) 
in Lebanon. The overall distribution of the prevalent emm types in the current study 
showed some common but yet variation in the distribution of the emm types, with the 
most prevalent reported being emm89 and emm12 followed by emm2 and emm1 with 
15%, 9%, 8% and 8%, respectively. This accounts for 40% of the isolates. The revealed 
types, excluding emm2, were strongly linked to cases of STSS, necrotizing fasciitis, 
cellulitis, arithritis, puerperal sepsis and meningitis by Luca-Harari et al. (2009), and 
even with fatal cases by Creti et al. (2007). A steady decrease in emm1, emm22 and 
emm28 and an increase in emm89, emm2 and emm12 were noted over a two year period. 
New emm types, not previously encountered in Lebanon, were also reported in this study 
and these include emm94 (1%), emm108 (6%) and emm118 (1%). Those three types 
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previously were mainly detected on the American continent (US, Brazil, Chile, 
Argentina) (Tanna et al. 2006). emm94 generally was found to be associated with 
Intravenous Drug Use (IDU), and was only detected in one isolate in this study. This 
finding is in harmony with the clode contact required for transmission (Tanna et al. 
2006). Furthermore, similar to our findings, emm118 was detected at low rate  
throughout studies conducted in Europe (Creti et al. 2007; Tanna et al. 2006; Luca-
Harari et al. 2007), and was not associated with any invasive infection. On the other 
hand, and contrary to the findings of Bahnan et al. (2011), emm3.19, emm29.2, 
emm97.1, emm110 and stC6979 were not detected in this study. Moreover, the recovered 
emm type distribution differed markedly from those reported by the CDC 
(http://www.cdc.gov/ncidod/biotech/strep/emmtype_proportions.html) with respect to 
the   prevalent GAS isolates in the Middle East (emm types 81, 14, 5 and 6) and Israel 
(Nir-Paz et al. 2010). emm types recovered in this study were additionally different from 
those reported in the USA (O’Loughlin et al. 2007), and the ones in European countries 
with emm types 81 and 89 prevailing in Sweden (30%) while emm28 in Denmark (26%) 
and Finland (45%) (Luca-Harari et al. 2009; Luca-Harari et al. 2008; Vlaminckx et al. 
2004). Interestingly, emm3 was not detected in our study, as was the case in other 
studies (Meisal et al. 2009; Tamayo et al. 2010). An upsurge of emm12 was previously 
reported to be associated with invasive infections in European children and scarlet fever 
in the Taiwanese (Meisel et al. 2010; Chiou et al. 2009) and an increase in emm1; most 
invasive type commonly associated with necrotizing fasciitis and bacteremia (Luca-
Harari et al. 2008). Different emm types prevailed in different age groups, with none 
being uniquely confined to a particular age group. emm12, however, was common 
among 3-11 years old patients, which was consistent with the findings of Meisal et al. 
(2010).  It is more worthy that 41 distinct emm types were detected among the 150 
isolates which reflects a high heterogeneity compared to other countries including the 
previously conducted study in Lebanon where 28 emm types were reported (Tappe et al. 
2011; Ma et al. 2011; Bahnan et al. 2011). This indicated the lack of a geographical 
stability within S. pyogenes prevailing in this country (Bahnan et al. 2011). 
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 Rantala et al. (2012) showed that the role of SAgs in the invasiveness of GAS 
diseases is much more important compared to emm types. In this study, seven 
predominant exotoxin gene profiles were detected with “SpeB, SpeG” dominating in 
11% of the isolates, followed by “SpeB, SpeK” (7%) and SpeB, SpeG, ssa (5%). The 
predominant profile was mainly prevalent in emm12 and emm89, a combination linked 
to puerperal sepsis and cellulitis cases (Luca-Harari et al. 2009). However, in contrast to 
other studies (Commons et al. 2008; Meisal et al. 2010; Ma et al. 2011; Rantala et al. 
2012), no specific restriction to superantigen profiles amongst individual emm types was 
found.  
 Knowledge about the role of streptococcal superantigens in disease manifestation 
and pathogenesis has expanded over the years (Rantala et al. 2012). Hence, distribution 
of superantigen genes has been used as an epidemiological tool to further investigate 
genomic heterogeneity and any probable toxin gene-disease association (Ma et al. 2011). 
With regard to the virulence gene repertoires, the distribution of toxin genes carried by 
each of the hundred isolates tested in the present work is remarkable. The frequencies of 
carriage of the streptococcal pyrogenic exotoxin B encoding gene (SpeB), known now as 
the cysteine protease, is highly prevalent in several studies conducted in which 100% 
prevalence was observed (Meisel et al. in 2010; Hraoui et al. in 2010; Watanabe et al. 
2002). The presence of SpeB in the isolates undertaken in this study was remarkable 
(87%), with SpeA and SpeC which are the two most extensively studied superantigens 
for their variability among strains, having the most variable reported frequencies. The 
prevalence of SpeA (28%) reported was in line with several other studies conducted in 
Denmark, Belgium (25% in each) and USA (26%), but higher than what was reported 
from Sweden, Italy (19% each), Australia (7-15%), India (8%) and Taiwan (4%) 
(Ekelund et al. 2005; Descheemaeker et al. 2000; Legiardo et al. 1993; Darenberg et al. 
2007; DelVecchio et al. 2002; Nandi et al. 2002; Bianco et al. 2006; Hsueh et al. 1997). 
On the other hand, SpeC was detected in only 1% of the isolates which was of emm type 
ST5345.1. Co-detection of SpeA and SpeC was often observed by several studies, which 
was not the case in this study (Commons et al. 2008; Alouf and Muller-Alouf, 2003). 
The detection of SpeA or SpeC was previously found to be associated with invasive 
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diseases namely STSS, the most common form of invasive streptococcal disease with 
50% mortality rate, were reportedly linked to either of the two toxin genes, while both 
were detected in bacteremic cases (Luca-Harari et al. 2008; Imhol et al. 2009; Hraoui et 
al. 2011; Rantala et al. 2012). A high SpeA incidence was seen in almost all emm1 type 
and subtypes (emm1.11, 1.44, 1.51 and 1.57); SpeA- emm1 combination was often 
involved in severe infections namely high Chronic Renal Failures (CRFs) (Luca-Harari 
et al. 2008). SpeA was detected in this study in other emm types as well (emm types 22, 
49, 75, 85, 89, ST041 and others), a finding rarely reported in other studies.  
 SpeJ is chromosomally encoded, and found in 11% of the isolates, which is 
considered to be low compared to other studies done by Proft et al. (2003), Schmitz et al. 
(2003) and Commons et al. (2008); these studies have reported 100%, 33% and 51% 
prevalence respectively. Furthermore, ssa was detected in 36% of the isolates which was 
relatively similar to what was reported from Europe and China (23% in each) (Schmitz 
et al. 2003; Jing et al. 2006). The prevalence of ssa was highly associated with invasive 
isolates as suggested with several studies illustrating its role in invasive diseases 
(Schmitz et al. 2003; Jing et al. 2006).  
 SpeK, SpeL and SpeM were found in 20%, 22% and 3% respectively. Thus, the 
three superantigens were more prevalent than that detected in Melbourne and New 
Zealand (Commons et al. 2008; Proft et al. 2003). Those superantigens are associated 
with acute rheumatic fever, which is a post-infection sequelae responsible for paediatric 
heart disease (Smoot et al. 2002; Proft et al. 2003). Despite the fact that SpeL and SpeM 
are carried adjacently on the same bacteriophage and their persistent co-detection was 
shown by several studies, SpeL and SpeM were never co-detected in this study (Smoot et 
al. 2002; Igwe et al. 2003; Proft et al. 2003).  
 SpeI (1%) was found in a single isolate along with SpeA and SpeB, and was 
typed as emm1.57. This was in line with the findings of Meisal et al. (2010) in Norway 
suggesting travel carriage. The low prevalence of SpeI can be explained by the potential 
of the gene to be lost during phage integration into the genome (Commons et al. 2008). 
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 Antimicrobial resistance is an important drawback in the management of 
patients with infectious diseases (Ciftci et al. 2003; Ndiaye et al. 2009). Penicillin G 
remains the antibiotic of choice for the treatment of GAS infections (Imohl et al. 2010). 
All isolates tested in this study were susceptible to penicillin G, ampicillin, gentamycin, 
teicoplanin, vancomycin and quinupristin/dalfoprustin, with 23% of the isolates being 
resistant to erythromycin. This, however, is relatively high compared to Italy (4%), 
Tunisia (5%) and Argentina (<1%). Erythromycin resistance rates in Europe were highly 
variable varying from 2% in UK, 10% in Sweden, to 17% in Finland (Ceftci et al. 2003; 
Mzoughi et al. 2004; Hraoui et al. 2010; Jasir et al. 2003). Erythromycin resistant S. 
pyogenes strains increased from 10% to 23% compared to results reported by Bahnan et 
al. (2011), this may be due to their association to emm types 12, 28 and 89 that 
remarkably increased in Lebanon during the last 2 years. Similar findings were reported 
by Hraoui et al. (2011) with emm12 and emm28. Three isolates showed also resistance to 
tetracycline and clindamycin, suggesting a link to the multiresistant European clone 
(Mihaila-Amrouche and Loubineux, 2004). 
 Additionally, 13% of the isolates were resistant to clindamycin, of those, only 
5% were also resistant to erythromycin with 1% showing the iMLSB phenotype, 3% the 
cMLSB mediating resistance through either ermA or ermB genes, and 2% showing the  
M phenotype mediating resistance to the 14-15 membered ring macrolides through mefA 
gene. This was in harmony with Bahnan et al. (2011) findings where 3% of isolates were 
shown to be resistant to erythromycin, 1% showed the iMLSB phenotype and 3% the 
cMLSB, with the absence of the M phenotype. The M phenotype is frequently 
encountered in countries with low erythromycin resistance incidence such as Finland, 
Greece, Germany, Italy, USA and Canada (Ardanuy et al. 2010). In contrast, the 
presence of the M phenotype in this study was associated with high levels of 
erythromycin resistance.  
Resistance to tetracycline was unexpectedly high, although its use has already 
decreased due to worldwide upsurge of resistance. Tetracycline resistance is often 
associated with transfer of the tet genes with the aid of mobilizable plasmids and 
transposons within species and genera (Roberts 2012), which explains the high 
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percentage of tetracycline resistance observed. Previous high tetracycline resistant rates 
were detected in Denmark (30%) and Senegal (100%) as well (Nielsen et al. 2002; 
Ndiaye et al. 2009). Tetracycline resistance was not restricted to certain emm types but 
distributed among 17 different ones. It is well known that the association of macrolides 
and tetracycline is related to the presence of the transposons Tn916 family (Ardanuy et 
al. 2010); 5% of the isolates in this study showed resistance to clarithromycin and 
tetracycline, while one percent was resistant to clarithromycin, erythromycin and 
tetracycline.  
With respect to antibiotic resistance and superantigen profiles, 16 antibiotic 
resistant profiles were generated. Most superantigenic profiles were associated with 
tetracycline resistance, followed by clarithomycin-tetracycline, and erythromycin. The 
majority of superantigens recovered within the tetracycline resistant isolates were SpeB 
and ssa, while SpeA and ssa were found in clarithomycin-tetracycline and erythromycin 
resistant isolates. The fact that tetracycline resistance is carried by mobilizable plasmids 
and transposons that could be easily transferred among isolates explains the 
predominance of tetracycline resistance seen amongst all superantigen carrying isolates. 
 Since new generation of quinolones represents the second alternative option for 
ß-lactam allergic patients, rate of macrolide-quinolones co-resistance has become a 
major predicament (Aradanuy et al. in 2010).  In our study, a variable rate of resistance 
was detected for quinolones: 13% to ciprofloxacin (2
nd
 generation quinolone) and 5% to 
levofloxacin (3
rd
 generation quinolone). These rates are considered to be very high when 
compared to Europe (0.14%), North America (0.51%) and some of the Baltic European 
countries (Gracia et al. 2009; Biedenbach et al., 2006). Second and third generation 
quinolone resistant strains belonged mainly to emm types 1, 9 and 22, which are the 
common types contributing to pharyngitis and severe diseases in the Middle East (CDC 
website).  
 Finally, 33 resistant profiles were detected among GAS isolates in this study 
with emm12 and emm89 appearing in almost every single resistant profile observed. 
Three isolates typed as emm1, emm2 and emm89 were found to be multidrug resistant 
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for six different antibiotics including clindamycin, tetracyclines, ciprofloxacin, 
erythromycin, clarithromycin and chloramphenicol. It can be deduced that decreased 
susceptibility to different antibiotics may be playing a crucial role in the pathogenicity of 
these emm types specifically that these types are considered  to be the  most invasive 
among the ones responsible for fatal diseases (Creti et al. 2007). 
 In conclusion, to our knowledge this study is the first that employs emm typing, 
superantigen and antibiotic resistance profiling in Lebanon. A wide diversity of emm 
types was observed amongst all tested isolates which calls the attention for the need to 
implement infection control majors aiming to limit the spread of GAS diseases. This 
study additionally highlighted the role and distribution of superantigens among GAS 
isolates. The toxin genes ssa, SpeA, SpeK and SpeL, previously associated with invasive 
infections, were detected in relatively high rates (36%, 28%, 20% and 22%, 
respectively). However, the repertoire of superantigens in our isolates seems to correlate 
to the emm types in an ambiguous complex pattern, hence excluding the configuration of 
any clear cut correlation toward the role of those superantigens in severe diseases. The 
upsurge in resistance rates against erythromycin, tetracylines and quinolones (23.3%, 
37.3% and 27% respectively) found in this study revealed that antibiotic resistance of S. 
pyogenes is a significant problem in Lebanon. Our results confirm that penicillin or its 
derivatives is still the drug of choice for GAS infections, and that macrolides, 
lincosamides and quinolones susceptibility testing should be performed as part of 
primary evaluation to direct antimicrobial therapy. Continuous surveillance studies are 
indispensable for understanding the nature of local epidemiology of GAS in Lebanon 
and to promote successful clinical therapy on the long term. Limitations of our study 
include the absence of clinical patient history that would have given us key information 
about the invasiveness of GAS isolates when compared to toxin gene profiling and 
antibiotic resistance patterns. 
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CHAPTER SIX 
CONCLUSION 
 
 This study provides a comprehensive overview of the epidemiology of GAS in 
Lebanon with the employment of emm typing, superantigen and antibiotic susceptibility 
profiling. 
 A pronounced diversity was demonstrated amongst all isolates. 
 emm typing showed the predominance of emm89 (16%) followed by emm12 (10%), 
emm2 (9%), and emm1 (8%). 
 To our knowledge, this study is the first in Lebanon that highlights the role and 
distribution of superantigens among GAS isolates. 
 The predominant detected superantigens were SpeB, ssa and SpeG in 87%, 36% and 
30% of the isolates respectively. 
 Seven predominant exotoxin gene profiles were detected with “SpeB, SpeG” being 
the predominant found in 11% of the isolates, followed by “SpeB, SpeK” (7%) and 
SpeB, SpeG, ssa (5%).  
 All isolates tested in this study were susceptible to penicillin G, ampicillin, 
gentamycin, teicoplanin, vancomycin and quinupristin/dalfoprustin. 
 Thirty-three distinct resistant profiles were generated with most prevalent phenotypes 
accounted for erythromycin (16%), clindamycin (9.3%) and tetracycline-clarithromycin 
(5.3%) respectively. 
 Accessibility of accurate typing techniques that offers cost effective intervention and 
prevention strategies remains crucial for the continuous surveillance studies that aim at 
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understanding the nature of local epidemiology of GAS in Lebanon and promoting 
successful clinical therapies on the long term. 
 Future larger studies that include larger number of samples as well as access of 
patient clinical history is important in order to keep track of the prevailing types, 
determine their genetic relationships, as well as define international dissemination 
levels. 
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ANNEX 
List of all the emm types found among our isolates, along with their antibiotic resistance and superantigen profiles 
Sample ID Sex Age Specimen emm type Antibiotic resistance Superantigen profile 
SN 1 M 9 Swab, throat 6 TET SpeB - SpeK 
SN 2 F 34 Swab, throat 49 ERY SpeA - SpeH - SpeJ - Spek 
SN 3 M 22 Swab, throat 108 TET SpeB - SpeJ 
SN 4 F 43 Swab, throat 75 
  
SN 5 M 26 Swab, throat 28 CHL - ERY – TET 
 
SN 6 M 47 Swab, throat 1 
 
SpeB - smeZ 
SN 7 M 24 Swab, throat 9 
CLA - CIP - LEV - TET - 
CLI SpeB - ssa 
SN 8 M 20 Swab, throat 11 
  
SN 9 M 12 Swab, throat STC5345.1 TET SpeG - SpeK- ssa 
SN 10 F 7 Swab, throat 12.1 OFL - ERY - TET 
 
SN 11 M 18 Swab, throat 6 
 
SpeB - SpeK 
SN 12 F 48 Swab, throat 11 TET 
 
SN 13 F 17 Swab, throat STG7882.1 
 
SpeA - SpeB - SpeG 
SN 14 F 16 Swab, throat 12.1 TET 
 
SN 15 F 48 Swab, wound 9 ERY SpeB - ssa 
SN 16 M 5 Swab, throat 22 TET SpeA - SpeB - ssa 
SN 17 M 24 Swab, throat 77 LEV - CLI SpeB - smeZ 
SN 18 M 5 Swab, throat 2 
CHL - CLA - ERY - CIP - 
TET - CLI 
 
SN 19 M 7 Swab, throat 89 LEV - TET - CLI SpeB - SpeL 
SN 20 F 9 Swab, throat 2 
  
SN 21 F 48 Swab, throat 12 CHL - CIP SpeB - SpeL 
SN 22 F 59 Swab, throat 29.2 ERY SpeB - SpeK 
SN 23 F 47 Swab, pus 108 CLA - TET SpeB - SpeL 
SN 24 M 6 Swab, throat STG7882.1 
 
SpeA - SpeB- SpeG 
SN 25 M 7 Swab,throat 89 
 
SpeB - SpeL 
SN 26 M 5 Swab,throat 76 TET SpeB - ssa 
SN 27 M 3 Swab,throat 2 ERY - TET SpeB - SpeJ - SpeK - ssa 
SN 28 M 7 Swab,throat 75 ERY SpeK – SpeL 
SN 29 F 5 Swab,throat STG7882.1 
 
SpeA - SpeB- SpeG 
SN 30 M 18 Swab,throat 6 
 
SpeB – SpeL 
SN 31 M 26 Swab,throat 1.11 CLA - TET SpeA – SpeB 
SN 32 M 28 Swab,throat 22 
 
SpeA - SpeB - ssa 
SN 33 M 3 Swab,throat 75 
 
SpeA - SpeB - Spe L 
SN 34 F 9 Swab,throat STG7882.1 ERY SpeA - SpeB - SpeG 
SN 35 M 5 Swab,throat 22 
 
SpeB – SpeG 
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SN 36 F 36 Swab,throat 22 CLA -TET SpeB – SpeG 
SN 37 M 85 Swab, pus 11 
  
SN 38 F 40 Swab, pus 28 
  
SN 39 M 3 Swab, throat 1 TET SpeB – smeZ 
SN 40 F 9 Swab, throat 2 
  
SN 41 M 4 Swab, throat 1.57 
 
SpeA - SpeB - SpeI 
SN 42 F 2 Swab, throat 2 ERY - CIP - TET- CLI 
 
SN 43 M 3 Swab, throat 89 
CHL- CLA- ERY - CIP - 
TET - CLI 
 
SN 44 M 3 Swab, throat 2 
  
SN 45 M 3 Swab, throat 9 
  
SN 46 M 4 Swab, throat 2 
  
SN 47 M 4 Swab, throat 89 CLA - ERY - CIP - TET 
 
SN 48 F 10 Swab, throat 12 ERY 
 
SN 49 M 8 Swab, throat 89 CHL 
 
SN 50 M 11 Swab, throat 89 TET 
 
SN 51 F 11 Swab, throat non-typeable CHL - TET - CLI 
 
SN 52 M 5 Swab, throat 75 
  
SN 53 F 4 Swab, throat 29.2 CHL 
 
SN 54 F 3 Swab, throat 1 
CHL - CLA - ERY - CIP - 
LEV - TET - CLI 
 
SN 55 M 5 Swab, throat non-typeable 
  
SN 56 F 8 Swab, pus 22 
  
SN 57 M 6 Swab, throat 28 ERY 
 
SN 58 M 5 Swab, throat 1 TET SpeA -  SpeB - SpeL 
SN 59 M 8 Swab, throat 28 
 
SpeB - SpeL - ssa 
SN 60 F 7 Swab, throat 12 
CHL - CLA - ERY - CIP - 
TET - CLI 
 
SN 61 M 5 Swab, throat 89 ERY 
 
SN 62 M 5 Swab, throat 12.7 TET 
 
SN 63 F 7 Swab, throat 11 
 
SpeB - SpeG - smeZ 
SN 64 F 8 Swab, throat 6 TET SpeB - SpeK - ssa 
SN 65 F 6 Swab, throat 12 
 
SpeB - SpeL - ssa 
SN 66 M 47 Swab, throat 108 ERY 
 
SN 67 M 47 Swab, throat 4 
 
SpeB - SpeG - SpeL - ssa 
SN 68 M 6 Swab, throat 28 
CHL - CLA - ERY - TET - 
CLI SpeB - SpeL - ssa 
SN 69 F 30 Swab, throat 75 
  
SN 70 M 35 Swab, pus 1 CLA - TET SpeA - SpeB - SpeL 
SN 71 F 10 Swab, throat 12 
  
SN 72 F 9 Swab, throat 6 
 
SpeB - SpeK - ssa 
SN 73 M 3 Swab, throat 1 
 
SpeB – ssa 
SN 74 M 4 Swab, throat 89 ERY - TET SpeB - SpeG - ssa 
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SN 75 F 23 Swab, throat 89 ERY SpeG 
SN 76 M 1 Swab, throat 28 
 
SpeB – ssa 
SN 77 M 4 Swab, throat 29.2 CLA SpeB – SpeG 
SN 78 M 34 Swab, throat 12.1 
 
SpeB - SpeG - ssa 
SN 79 M 3 Swab, throat 108 
  
SN 80 M 4 Swab, throat 22 ERY SpeA - SpeB - ssa - smeZ 
SN 81 F 2 Swab, throat 75 
  
SN 82 F 7 Swab, throat 89 TET 
 
SN 83 M 5 Swab, throat 1 
  
SN 84 F 23 Swab, throat STC6779.0 
 
SpeB – smeZ 
SN 85 F 1 Swab, throat 85 ERY SpeA - SpeH - ssa 
SN 86 F 9 Swab, throat 12 CLA - TET - CLI SpeB - SpeL - ssa 
SN 87 F 3 Swab, throat 77 CLA SpeB – SpeJ 
SN 88 F 12 Swab, throat 2 TET 
 
SN 89 M 5 Swab, throat 75 CLA - ERY SpeB – SpeK 
SN 90 M 4 Swab, throat 1.51 TET SpeA – SpeB 
SN 91 F 8 Swab, throat 89 ERY 
 
SN 92 M 45 Swab, throat 1 
 
SpeA – SpeB 
SN 93 F 3 Swab, throat 13 
 
SpeB – ssa 
SN 94 M 5 Swab, throat non-typeable TET 
 
SN 95 F 7 Swab, throat 1.51 
 
SpeA – SpeB 
SN 96 M 3 Swab, throat 2 
 
SpeG - SpeH - SpeK - ssa 
SN 97 F 34 Swab, throat 89 CHL - CLA - ERY - CLI SpeA - SpeB - SpeG 
SN 98 F 12 Swab, throat 29.2 
  
SN 99 M 14 Swab, throat 89 
 
SpeB - SpeG - SpeJ 
SN 100 F 10 Swab, throat 2 
  
SN 101 M 7 Swab, throat STC5345.1 
 
SpeJ - SpeK - ssa 
SN 102 F 32 Swab, throat STG166B.0 CLA - ERY - TET SpeL – ssa 
SN 103 F 15 Swab, throat 89 
  
SN 104 M 3 Swab, throat 12 
 
SpeB - Spe\G - ssa 
SN 105 F 39 Swab, throat ST0412.0 
 
SpeA – SpeK 
SN 106 M 11 Swab, throat 12 
  
SN 107 F 16 Swab, throat non-typeable 
 
SpeA – SpeB 
SN 108 F 44 Swab, throat 89 TET SpeB - SpeG - SpeJ 
SN 109 M 6 Swab, throat 89 
 
SpeB – SpeG 
SN 110 F 49 Swab, throat 1 
 
SpeA - SpeB - SpeJ 
SN 111 M 9 Swab, throat 1 CLA - TET SpeA – SpeB 
SN 112 M 6 Swab, throat 89.1 TET SpeA - SpeB - SpeG 
SN 113 M 7 Swab, throat 118 
 
SpeB - SpeH - SpeK - smeZ 
SN 114 F 3 Swab, throat ST5240.0 CLA - ERY SpeA – SpeB 
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SN 115 F 6 Swab, throat 89 TET 
 
SN 116 M 11 Swab, throat 75 
 
SpeB - SpeL - ssa 
SN 117 M 22 Swab, throat 87 
 
SpeB – SpeG 
SN 118 M 6 Swab, throat 1 
 
SpeA - SpeB - SpeL 
SN 119 F 13 Swab, throat 89 CLA - TET SpeB – SpeK 
SN 120 M 5 Swab, throat 1.44 
 
SpeA - SpeB - SpeL 
SN 121 F 35 Swab, throat 94 
 
SpeB - SpeG - SpeL 
SN 122 F 6 Swab, throat non-typeable ERY - TET - CLI 
 
SN 123 M 7 Swab, throat ST3211.0 
 
SpeB – SpeK 
SN 124 M 35 Swab, throat 89 CLA - TET 
 
SN 125 M 3 Swab, throat 12 
 
SpeA - SpeB - SpeM - ssa 
SN 126 F 32 Swab, throat 
  
SpeB - ssa 
SN 127 F 56 Swab, throat STG652 
 
SpeB -  SpeK - SpeL - ssa 
SN 128 F 11 Swab, throat 6 ERY - TET SpeB - SpeL 
SN 129 F 10 Swab, throat 12.48 TET 
 
SN 130 M 11 Swab, throat 12 CLA SpeG - SpeK - ssa 
SN 131 M 13 Swab, throat 29.3 ERY - CIP- TET SpeB - SpeK 
SN 132 M 13 Swab, throat 89 TET SpeB - SpeJ - ssa 
SN 133 M 46 Swab, throat STGM220 
 
SpeB - SpeG - ssa 
SN 134 M 10 Swab, throat 
22 
CHL - AZI - ERY - CIP - 
LEV - TET SpeB - SpeJ - Spe L 
SN 135 F 91 swab, pus 108 CIP SpeB - SpeG - smeZ 
SN 136 F 55 Swab, throat STC1400 
 
SpeB - SpeG 
SN 137 M 19 Swab, throat 89 CLA SpeB - SpeH - ssa 
SN 138 F 30 Swab, throat 2.2 TET SpeA - SpeM - ssa 
SN 139 M 2 Swab, throat 75 
  
SN 140 F 19 Swab, throat 2 ERY SpeB - SpeG 
SN 141 M 4 Swab, throat 12 CLA 
 
SN 142 M 4 Swab, throat 2 TET SpeB - SpeG 
SN 143 M 11 Swab, throat 29.2 
 
SpeB 
SN 144 F 10 Swab, throat 89 CLA - ERY - TET SpeB - SpeG 
SN 145 F 37 Swab, throat 12.7 
 
SpeB - SpeG 
SN 146 M 3 Swab, throat 12 CIP -TET SpeM - ssa 
SN 147 F 10 Swab, throat 108 
 
SpeB - ssa 
SN 148 F 8 Swab, throat 108 CLA - TET SpeB - SpeJ 
SN 149 M 8 Swab, throat 12 ERY - CIP - TET SpeB - SpeJ 
SN 150 F 47 Swab, throat 108 
 
SpeB - SpeC - SpeK 
SN 151 M 28 Swab, throat STC5345.1 TET 
  
